公开(公告)号：US20110311560A1

公开(公告)日：2011-12-22

申请号：US13084239

申请日：2011-04-11

申请人： BING MA ,  JACK A. ELIAS

发明人： BING MA ,  JACK A. ELIAS

IPC分类号： A61K31/439 ,  A61P37/06 ,  A61P11/00

CPC分类号： C07K16/2866 ,  A61K2039/505

摘要： The present invention includes compositions and methods for the treatment of Th1 and/or Th2 mediated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5, mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and that inhibiting CCR5 treats, and even prevents, the diseases. Thus, the invention relates to the novel discovery that inhibiting CCR5 treats and prevents Th1 and/or Th2 mediated inflammatory disease.

摘要翻译： 本发明包括用于治疗与抑制CCR5有关的Th1和/或Th2介导的炎性疾病的组合物和方法。 这是因为本发明首次表明IFN-γ，IL-13和CCR5的表达介导和/或与Th1和/或Th2炎性疾病相关，并且抑制CCR5治疗，甚至预防 ，疾病。 因此，本发明涉及抑制CCR5治疗和预防Th1和/或Th2介导的炎性疾病的新发现。